Home / Business and Economy / Sun Pharma Eyes $10B Women's Health Buyout
Sun Pharma Eyes $10B Women's Health Buyout
19 Jan
Summary
- Sun Pharma considers acquiring US-based Organon for $10 billion.
- Organon specializes in women's health and biosimilars.
- The deal could be the largest cross-border pharma acquisition from India.
Sun Pharma, India's largest pharmaceutical company, is reportedly evaluating a substantial acquisition of US-based Organon, a firm focused on women's health and biosimilars. The potential deal is valued at approximately $10 billion, inclusive of debt. This acquisition would represent a significant strategic expansion for Sun Pharma, aiming to strengthen its foothold in the competitive United States market.
Organon, originally spun out from MSD (Merck Sharp & Dohme) in 2021, carries a considerable debt load, with reports indicating $8.9 billion by the second quarter of 2025. The company has pursued inorganic growth, including a $1.2 billion acquisition of Dermavant in September 2024. However, Organon has also been divesting certain businesses to streamline operations and improve its financial standing.
This potential takeover, if successful, would be a landmark cross-border acquisition for the Indian pharmaceutical sector. Sun Pharma, known for its expertise in turning around financially challenged companies, is seen as a strong candidate to integrate and improve Organon's operations. Experts suggest the combined entity would benefit from Organon's specialized portfolio and Sun Pharma's established commercial infrastructure.
